Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial

MA. Sekeres, P. Montesinos, J. Novak, J. Wang, D. Jeyakumar, B. Tomlinson, J. Mayer, E. Jou, T. Robak, DC. Taussig, H. Dombret, A. Merchant, N. Shaik, T. O'Brien, W. Roh, X. Liu, W. Ma, CG. DiRienzo, G. Chan, JE. Cortes

. 2023 ; 37 (10) : 2017-2026. [pub] 20230821

Language English Country England, Great Britain

Document type Randomized Controlled Trial, Clinical Trial, Phase III, Journal Article

Persistent link   https://www.medvik.cz/link/bmc24001156

This is the primary report of the randomized, placebo-controlled phase 3 BRIGHT AML 1019 clinical trial of glasdegib in combination with intensive chemotherapy (cytarabine and daunorubicin) or non-intensive chemotherapy (azacitidine) in patients with untreated acute myeloid leukemia. Overall survival (primary endpoint) was similar between the glasdegib and placebo arms in the intensive (n = 404; hazard ratio [HR] 1.05; 95% confidence interval [CI]: 0.782-1.408; two-sided p = 0.749) and non-intensive (n = 325; HR 0.99; 95% CI: 0.768-1.289; two-sided p = 0.969) studies. The proportion of patients who experienced treatment-emergent adverse events was similar for glasdegib versus placebo (intensive: 99.0% vs. 98.5%; non-intensive: 99.4% vs. 98.8%). The most common treatment-emergent adverse events were nausea, febrile neutropenia, and anemia in the intensive study and anemia, constipation, and nausea in the non-intensive study. The addition of glasdegib to either cytarabine and daunorubicin or azacitidine did not significantly improve overall survival and the primary efficacy endpoint for the BRIGHT AML 1019 phase 3 trial was not met. Clinical trial registration: ClinicalTrials.gov: NCT03416179.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24001156
003      
CZ-PrNML
005      
20240418103133.0
007      
ta
008      
240109s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41375-023-02001-z $2 doi
035    __
$a (PubMed)37604981
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Sekeres, Mikkael A $u Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA. msekeres@med.miami.edu $1 https://orcid.org/0000000320096524
245    10
$a Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial / $c MA. Sekeres, P. Montesinos, J. Novak, J. Wang, D. Jeyakumar, B. Tomlinson, J. Mayer, E. Jou, T. Robak, DC. Taussig, H. Dombret, A. Merchant, N. Shaik, T. O'Brien, W. Roh, X. Liu, W. Ma, CG. DiRienzo, G. Chan, JE. Cortes
520    9_
$a This is the primary report of the randomized, placebo-controlled phase 3 BRIGHT AML 1019 clinical trial of glasdegib in combination with intensive chemotherapy (cytarabine and daunorubicin) or non-intensive chemotherapy (azacitidine) in patients with untreated acute myeloid leukemia. Overall survival (primary endpoint) was similar between the glasdegib and placebo arms in the intensive (n = 404; hazard ratio [HR] 1.05; 95% confidence interval [CI]: 0.782-1.408; two-sided p = 0.749) and non-intensive (n = 325; HR 0.99; 95% CI: 0.768-1.289; two-sided p = 0.969) studies. The proportion of patients who experienced treatment-emergent adverse events was similar for glasdegib versus placebo (intensive: 99.0% vs. 98.5%; non-intensive: 99.4% vs. 98.8%). The most common treatment-emergent adverse events were nausea, febrile neutropenia, and anemia in the intensive study and anemia, constipation, and nausea in the non-intensive study. The addition of glasdegib to either cytarabine and daunorubicin or azacitidine did not significantly improve overall survival and the primary efficacy endpoint for the BRIGHT AML 1019 phase 3 trial was not met. Clinical trial registration: ClinicalTrials.gov: NCT03416179.
650    _2
$a lidé $7 D006801
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $7 D000971
650    12
$a akutní myeloidní leukemie $7 D015470
650    _2
$a daunomycin $7 D003630
650    _2
$a cytarabin $7 D003561
650    _2
$a azacytidin $x terapeutické užití $7 D001374
650    12
$a anemie $x farmakoterapie $7 D000740
650    _2
$a nauzea $x farmakoterapie $7 D009325
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
700    1_
$a Montesinos, Pau $u Hospital Universitari i Politècnic La Fe, Valencia, Spain $u CIBERONC, Instituto Carlos III, Madrid, Spain $1 https://orcid.org/0000000232755593
700    1_
$a Novak, Jan $u Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic $u Department of Haematology, 3rd Faculty of Medicine, Charles University and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Wang, Jianxiang $u Department of Clinical Hematology, Institute of Hematology and Blood Diseases Hospital, Tianjin, China $1 https://orcid.org/0000000194379151
700    1_
$a Jeyakumar, Deepa $u University of California, Irvine, Chao Family Comprehensive Cancer Center, Orange, CA, USA
700    1_
$a Tomlinson, Benjamin $u Division of Hematology, University Hospitals of Cleveland Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA $1 https://orcid.org/0000000224070973
700    1_
$a Mayer, Jiri $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
700    1_
$a Jou, Erin $u Department of Hematology/Oncology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, USA
700    1_
$a Robak, Tadeusz $u Department of Hematology, Medical University of Lodz, Lodz, Poland $1 https://orcid.org/0000000234116357
700    1_
$a Taussig, David C $u The Royal Marsden Hospital, London, UK
700    1_
$a Dombret, Hervé $u Institut de Recherche Saint-Louis, Hôpital Saint-Louis Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France $7 xx0316388
700    1_
$a Merchant, Akil $u Division of Hematology and Cellular Therapy, Cedars Sinai Cancer, Los Angeles, CA, USA $1 https://orcid.org/000000017472822X
700    1_
$a Shaik, Naveed $u Pfizer Oncology, Pfizer Inc, San Diego, CA, USA
700    1_
$a O'Brien, Thomas $u Pfizer Oncology, Pfizer Inc, San Diego, CA, USA
700    1_
$a Roh, Whijae $u Pfizer Oncology, Pfizer Inc, San Diego, CA, USA
700    1_
$a Liu, Xueli $u Pfizer Oncology, Pfizer Inc, San Diego, CA, USA
700    1_
$a Ma, Wendy $u Pfizer Oncology, Pfizer Inc, San Diego, CA, USA
700    1_
$a DiRienzo, Christine G $u Pfizer Inc, Collegeville, PA, USA
700    1_
$a Chan, Geoffrey $u Pfizer Inc, Collegeville, PA, USA
700    1_
$a Cortes, Jorge E $u Georgia Cancer Center, Augusta, GA, USA. jorge.cortes@augusta.edu $1 https://orcid.org/0000000286361071
773    0_
$w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 37, č. 10 (2023), s. 2017-2026
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37604981 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240418103127 $b ABA008
999    __
$a ok $b bmc $g 2049639 $s 1210850
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 37 $c 10 $d 2017-2026 $e 20230821 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
LZP    __
$a Pubmed-20240109

Find record

Citation metrics

Archiving options